| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/07/2001 | WO2001064221A1 Low dose entecavir formulation and use |
| 09/07/2001 | WO2001064220A1 Use of trimetazidine to inhibit acyl-coa acetyl transferase |
| 09/07/2001 | WO2001064219A2 Use of cytoskeleton modifying compounds against intracranial pressure changes |
| 09/07/2001 | WO2001064218A2 Farnesyl protein transferase inhibitor combinations |
| 09/07/2001 | WO2001064217A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 09/07/2001 | WO2001064216A1 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity |
| 09/07/2001 | WO2001064215A1 Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2001064213A1 Compounds and methods |
| 09/07/2001 | WO2001064212A1 Modulators of the endocannabinoid uptake and of the vallinoid receptors |
| 09/07/2001 | WO2001064211A1 Specific therapeutic composition for treating aids |
| 09/07/2001 | WO2001064210A1 Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
| 09/07/2001 | WO2001064208A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064207A2 Methods of modulating cell-adhesion mediated drug resistance |
| 09/07/2001 | WO2001064206A2 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 09/07/2001 | WO2001064205A2 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 09/07/2001 | WO2001064204A2 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents |
| 09/07/2001 | WO2001064203A2 Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10? |
| 09/07/2001 | WO2001064202A2 Tramadol for the treatment of functional gastrointestinal disorders |
| 09/07/2001 | WO2001064201A2 Restricting reinstatement of drug use |
| 09/07/2001 | WO2001064200A2 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 09/07/2001 | WO2001064199A2 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 09/07/2001 | WO2001064198A2 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 09/07/2001 | WO2001064197A2 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 09/07/2001 | WO2001064196A2 Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| 09/07/2001 | WO2001064195A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 09/07/2001 | WO2001064194A2 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 09/07/2001 | WO2001064193A2 Exemestane for first-line treatment of breast cancer |
| 09/07/2001 | WO2001064192A2 Use of benzothieno-2,3-d-pyrimidines with pde v inhibitory effect for the treatment of erectile dysfunction |
| 09/07/2001 | WO2001064190A1 Rapidly disintegrable tablet containing polyvinyl alcohol |
| 09/07/2001 | WO2001064189A1 Coated granules and foaming compositions containing the same |
| 09/07/2001 | WO2001064187A2 Anaesthetic formulations |
| 09/07/2001 | WO2001064183A1 Orally administered controlled delivery system for once daily administration of ciprofloxacin |
| 09/07/2001 | WO2001064167A1 Cosmetic and pharmaceutical preparations for treating cellulite |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064164A2 Nanocapsule encapsulation system and method |
| 09/07/2001 | WO2001064149A1 Improved transdermal drug patch |
| 09/07/2001 | WO2001064148A1 Topically applied clotting material |
| 09/07/2001 | WO2001064057A1 Novel pharmaceutical or dietetic mushroom-based compositions |
| 09/07/2001 | WO2001064034A1 Antimicrobial sanitizing lotion with skin protection properties |
| 09/07/2001 | WO2001052805B1 Anti-microbial compositions comprising a salt of a transition metal chelator |
| 09/07/2001 | WO2001043747A8 Matrix tablet for prolonged release of trimetazidine after oral administration |
| 09/07/2001 | WO2001022923A3 Scar treatment composition |
| 09/07/2001 | WO2001021167A8 Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein |
| 09/07/2001 | WO2001019823A3 Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| 09/07/2001 | WO2001019780A3 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001014331A3 Non-quinoline inhibitors of malaria parasites |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2001012804A3 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 09/07/2001 | WO2001012191A3 Pharmaceutical compositions comprising a 7-(2-aminoethyl)-benzothiazolone and a glucocorticoid |
| 09/07/2001 | WO2001010841A3 Fluorene derivatives as integrin inhibitors |
| 09/07/2001 | WO2001010423A3 Use of 5-ht3 receptor antagonists for the treatment of inflammations of the respiratory tract |
| 09/07/2001 | WO2001010408A3 Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2001007432A8 Aminopiperidine derivatives as antibacterials |
| 09/07/2001 | WO2001000197A3 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000071571A3 Fap-activated anti-tumor compounds |
| 09/07/2001 | WO2000062765A3 ESTROGEN RECEPTOR-β LIGANDS |
| 09/07/2001 | WO2000061127A3 Use of insulin sensitisers for improving ketosis |
| 09/07/2001 | WO2000054763A3 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone |
| 09/07/2001 | WO2000051584A3 Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
| 09/07/2001 | WO2000047603A9 16-hydroxyestratrienes as selective estrogens |
| 09/07/2001 | WO2000047203A9 Formulation and system for intra-oral delivery of pharmaceutical agents |
| 09/07/2001 | WO2000046389A9 Process for the preparation of pseudomonic acid a antibiotic by microbiological method |
| 09/07/2001 | WO2000042055A3 Macrolides with anti-inflammatory activity |
| 09/07/2001 | WO2000002912A3 Disintegrin homologs |
| 09/07/2001 | CA2401834A1 Novel imidazotriazinones and the use thereof |
| 09/07/2001 | CA2401800A1 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 09/07/2001 | CA2401775A1 Diagnostics and therapeutics for glaucoma |
| 09/07/2001 | CA2401704A1 Salmon-origin chondroitin sulfate |
| 09/07/2001 | CA2401697A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
| 09/07/2001 | CA2401673A1 Ningalin b analogs employable for reversing multidrug resistance |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401607A1 Methods for selectively modulating survivin apoptosis pathways |
| 09/07/2001 | CA2401606A1 Caspase-inhibitory-factor (cif) and uses thereof |
| 09/07/2001 | CA2401585A1 Use of pde v inhibitors |
| 09/07/2001 | CA2401533A1 Tcf responsive element |
| 09/07/2001 | CA2401489A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | CA2401405A1 Medicament for viral diseases |
| 09/07/2001 | CA2401352A1 Immune enhancement compositions and use thereof |
| 09/07/2001 | CA2401340A1 Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors |
| 09/07/2001 | CA2401336A1 Inhibitors of melanocyte tyrosinase as topical skin lighteners |
| 09/07/2001 | CA2401304A1 Combination chemotherapy |
| 09/07/2001 | CA2401173A1 G12l, a gene associated with the thermal response |
| 09/07/2001 | CA2401151A1 Anti-infective ectatm |
| 09/07/2001 | CA2401041A1 Breast cancer hormonal therapy |
| 09/07/2001 | CA2401022A1 Methods for treating fsh related conditions with gnrh antagonists |
| 09/07/2001 | CA2400950A1 Orally administered controlled delivery system for once daily administration of ciprofloxacin |
| 09/07/2001 | CA2400657A1 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | CA2400649A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | CA2400595A1 Human schizophrenia gene |
| 09/07/2001 | CA2400138A1 Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 09/07/2001 | CA2400116A1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 09/07/2001 | CA2399704A1 Pyrimidine compounds |
| 09/07/2001 | CA2398685A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | CA2397694A1 Farnesyl protein transferase inhibitor combinations |
| 09/07/2001 | CA2397690A1 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |